stockrowInsmed, Inc.
INSM Healthcare Biotechnology
Insmed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $606.4 million, up 66.7% from fiscal 2024.
- Revenue
- +268.4%
- EPS
- +73.8%
- Free cash flow
- +81.1%
- Total debt
- +0.27%
Quarter to September 2026, against a year earlier
Follow INSM
Alert me
Insmed, Inc. (INSM) Return on equity
Insmed, Inc.'s return on equity over the twelve months to 30 September 2026 was −72.5%, up 176.8 percentage points from fiscal 2025 (−249.3%). Over the past ten years it has ranged from −249.3% (fiscal 2025) to 3,926.5% (fiscal 2024) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of −50.1% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −249.3% | (4,175.77) |
| FY2024 | 3,926.5% | 3,312.02 |
| FY2023 | 614.5% | 807.69 |
| FY2022 | −193.2% | (66.56) |
| FY2021 | −126.7% | (17.24) |
| FY2020 | −109.4% | (1.18) |
| FY2019 | −108.2% | 5.68 |
| FY2018 | −113.9% | (39.18) |
| FY2017 | −74.7% | 0.88 |
| FY2016 | −75.6% | (28.15) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| ALNY Alnylam Pharmaceuticals, Inc. compare | 138.1% |
| ASND Ascendis Pharma A/S compare | 118.4% |
| EXEL Exelixis, Inc. compare | 44.3% |
| BBIO BridgeBio Pharma, Inc. compare | 26.2% |
| GMAB Genmab A/S Sponsored ADR compare | 14.0% |
| INCY Incyte Corporation compare | 7.84% |
| ROIV Roivant Sciences Ltd. compare | −5.47% |
| BNTX BioNTech SE Sponsored ADR compare | −8.29% |
| INSM Insmed, Inc. | −72.5% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on INSM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement